• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site

tetano

Editor, Senior Moderator
Adv Appl Bioinform Chem. 2013 Aug 19;6:47-53. doi: 10.2147/AABC.S49503.
Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site.
Narayanan MM, Nair CB, Sanjeeva SK, Rao PS, Pullela PK, Barrow CJ.
Source

Centre for Chemistry and Biotechnology, Deakin University, Geelong, VIC, Australia ; Bigtec Pvt Ltd, Rajajinagar, Bangalore, India.
Abstract

Viral neuraminidase inhibitors such as oseltamivir and zanamivir prevent early virus multiplication by blocking sialic acid cleavage on host cells. These drugs are effective for the treatment of a variety of influenza subtypes, including swine flu (H1N1). The binding site for these drugs is well established and they were designed based on computational docking studies. We show here that some common natural products have moderate inhibitory activity for H1N1 neuraminidase under docking studies. Significantly, docking studies using AutoDock for biligand and triligand forms of these compounds (camphor, menthol, and methyl salicylate linked via methylene bridges) indicate that they may bind in combination with high affinity to the H1N1 neuraminidase active site. These results also indicate that chemically linked biligands and triligands of these natural products could provide a new class of drug leads for the prevention and treatment of influenza. This study also highlights the need for a multiligand docking algorithm to understand better the mode of action of natural products, wherein multiple active ingredients are present.
KEYWORDS:

H1N1, binding energy, influenza, molecular docking, multiligand, neuraminidase, virus

PMID:
23983477
[PubMed]
PMCID:
PMC3751451

Free full text

http://www.ncbi.nlm.nih.gov/pubmed/23983477
 
Back
Top Bottom